Zidovudine/lamivudine/abacavir plus tenofovir in HIV-infected naive patients: A 96-week prospective one-arm pilot study

AIDS Research and Human Retroviruses

Volumn 24, Issue 7, 2008, Pages 931-934

  Ferrer, Elena ^a   Gatell, Jose Maria ^b   Sanchez, Pochita ^a   Domingo, Pere ^c   Puig, Teresa ^d   Niubo, Jordi ^a   Cortes, Cristina ^b   Veloso, Sergio ^e   Pedrol, Enric ^f   Leon, Agathe ^b   Gutierrez, Mar ^c   Podzamczer, Daniel ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d HOSPITAL ARNAU DE VILANOVA   (Spain)

^e HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^f HOSPITAL GENERAL DE GRANOLLERS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; TENOFOVIR;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CLINICAL EVALUATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATTY LIVER; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; VOMITING;

ADENINE; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DIDEOXYNUCLEOSIDES; ENDPOINT DETERMINATION; FEMALE; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; PILOT PROJECTS; PROSPECTIVE STUDIES; SPAIN; TREATMENT OUTCOME; VIRAL LOAD; ZIDOVUDINE;

EID: 48749124843     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2007.0271     Document Type: Article

References (14)

1. Hadigan C, Meigs JB, Corcoran C, et al.: Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001;32:130-139.
2. Gallego L, Barreiro R, Del Río R, et al.: Analyzing sleep abnormalities in HIV infected patients treated with efavirenz. Clin Infect Dis 2004;8:430-432.
3. Gulick RM, Ribaudo HJ, Shikuma CM, et al.: Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. New Engl J Med 2004;350:1850-1861.
4. Farthing C, Kanlouh H, and Yeh V: Early virologic failure in a pilot study evaluating the efficacy of abacavir, lamivudine and tenofovir in the treatment of naive HIV-infected patients. Presented at the 2nd IAS Conference on HIV Pathogenesis and Treatment, July 13-17, 2003, Paris. Abstract 43.
5. Miller MD: K65R, TAMs and tenofovir. AIDS Rev 2004;6:22-23.
6. Parikh UM, Bacheler L, Koontz D, and Mellors JW: The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations. J Virol 2006;80:4971-4977.
7. Elion R, Cohen C, DeJesus E, et al.: Once-daily abacavir/lamivudine/zidovudine plus tenofovir for the treatment of HIV-1 infection in antiretroviral-naive subjects: A 48-week pilot study. HIV Clin Trials 2006;7:324-333.
8. Podzamczer D, Ferrer E, Sanchez P, et al.: Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. J Acquir Immune Defic Syndr 2007;44:139-147.
9. Gallant, JE, DeJesus E, Arribas JR, et al.: Tenofovir emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006;354:251-260.
10. Stürmer M, Staszewski S, and Doerr HW: Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV. Antiviral Ther 2007;12:695-703.
11. Eron J Jr, Yeni P, Gathe J Jr, et al.: The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: A randomised non-inferiority trial. Lancet 2006;368:476-482.
12. DART Virology Group and Trial Team: Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. AIDS 2006;20:1391-1399.
13. Rey D, Krebs M, Partisani M, et al.: Virologic response of zidovudine, lamivudine, and tenofovir disoproxil fumarate combination in antiretroviral-naive HIV-1-infected patients. J Acquir Immune Defic Syndr 2006;43:530-534.
14. Moyle G, Higgs C, Teague A, et al.: An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy. Antiviral Ther 2006;11:73-78.